nodes	percent_of_prediction	percent_of_DWPC	metapath
Amprenavir—Cytochrome P450 3A4 Inhibitors—Cyclosporine—psoriasis	0.594	1	CiPCiCtD
Amprenavir—CYP2C8—Tazarotene—psoriasis	0.0258	0.0794	CbGbCtD
Amprenavir—CYP3A5—Beclomethasone—psoriasis	0.0249	0.0768	CbGbCtD
Amprenavir—ABCC1—Cyclosporine—psoriasis	0.0203	0.0625	CbGbCtD
Amprenavir—CYP2B6—Cholecalciferol—psoriasis	0.0145	0.0447	CbGbCtD
Amprenavir—CYP2D6—Hydroxyurea—psoriasis	0.0116	0.0357	CbGbCtD
Amprenavir—CYP2C8—Cholecalciferol—psoriasis	0.011	0.0339	CbGbCtD
Amprenavir—ABCC1—Methotrexate—psoriasis	0.0107	0.0331	CbGbCtD
Amprenavir—CYP3A5—Mycophenolate mofetil—psoriasis	0.00993	0.0306	CbGbCtD
Amprenavir—CYP2C8—Mycophenolate mofetil—psoriasis	0.00955	0.0294	CbGbCtD
Amprenavir—CYP2C19—Cholecalciferol—psoriasis	0.00924	0.0284	CbGbCtD
Amprenavir—CYP3A4—Calcitriol—psoriasis	0.00867	0.0267	CbGbCtD
Amprenavir—CYP3A5—Hydrocortisone—psoriasis	0.00797	0.0245	CbGbCtD
Amprenavir—CYP2C9—Cholecalciferol—psoriasis	0.00768	0.0236	CbGbCtD
Amprenavir—CYP2C8—Hydrocortisone—psoriasis	0.00766	0.0236	CbGbCtD
Amprenavir—CYP3A5—Cyclosporine—psoriasis	0.00752	0.0232	CbGbCtD
Amprenavir—CYP2C8—Cyclosporine—psoriasis	0.00723	0.0223	CbGbCtD
Amprenavir—CYP2D6—Cholecalciferol—psoriasis	0.00702	0.0216	CbGbCtD
Amprenavir—CYP3A4—Methoxsalen—psoriasis	0.00674	0.0207	CbGbCtD
Amprenavir—ABCB1—Mycophenolate mofetil—psoriasis	0.00646	0.0199	CbGbCtD
Amprenavir—CYP2C19—Prednisone—psoriasis	0.0064	0.0197	CbGbCtD
Amprenavir—CYP2B6—Dexamethasone—psoriasis	0.00629	0.0194	CbGbCtD
Amprenavir—CYP2C19—Cyclosporine—psoriasis	0.00607	0.0187	CbGbCtD
Amprenavir—ABCB1—Betamethasone—psoriasis	0.00554	0.0171	CbGbCtD
Amprenavir—ABCB1—Prednisolone—psoriasis	0.00547	0.0168	CbGbCtD
Amprenavir—ABCB1—Hydrocortisone—psoriasis	0.00519	0.016	CbGbCtD
Amprenavir—ABCB1—Prednisone—psoriasis	0.00517	0.0159	CbGbCtD
Amprenavir—CYP2C9—Cyclosporine—psoriasis	0.00505	0.0155	CbGbCtD
Amprenavir—CYP3A5—Dexamethasone—psoriasis	0.00495	0.0152	CbGbCtD
Amprenavir—ABCB1—Cyclosporine—psoriasis	0.0049	0.0151	CbGbCtD
Amprenavir—CYP2C8—Dexamethasone—psoriasis	0.00476	0.0147	CbGbCtD
Amprenavir—CYP2D6—Cyclosporine—psoriasis	0.00461	0.0142	CbGbCtD
Amprenavir—CYP3A4—Cholecalciferol—psoriasis	0.00447	0.0137	CbGbCtD
Amprenavir—CYP2C19—Dexamethasone—psoriasis	0.004	0.0123	CbGbCtD
Amprenavir—CYP3A4—Triamcinolone—psoriasis	0.00387	0.0119	CbGbCtD
Amprenavir—CYP3A4—Mycophenolate mofetil—psoriasis	0.00387	0.0119	CbGbCtD
Amprenavir—CYP2C9—Dexamethasone—psoriasis	0.00332	0.0102	CbGbCtD
Amprenavir—CYP3A4—Betamethasone—psoriasis	0.00332	0.0102	CbGbCtD
Amprenavir—CYP3A4—Prednisolone—psoriasis	0.00328	0.0101	CbGbCtD
Amprenavir—ABCB1—Dexamethasone—psoriasis	0.00322	0.00992	CbGbCtD
Amprenavir—CYP3A4—Hydrocortisone—psoriasis	0.00311	0.00956	CbGbCtD
Amprenavir—CYP3A4—Prednisone—psoriasis	0.00309	0.00953	CbGbCtD
Amprenavir—CYP2D6—Dexamethasone—psoriasis	0.00304	0.00935	CbGbCtD
Amprenavir—CYP3A4—Cyclosporine—psoriasis	0.00293	0.00903	CbGbCtD
Amprenavir—ABCB1—Methotrexate—psoriasis	0.00259	0.00798	CbGbCtD
Amprenavir—CYP3A4—Dexamethasone—psoriasis	0.00193	0.00595	CbGbCtD
Amprenavir—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.000777	0.0609	CbGpPWpGaD
Amprenavir—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000658	0.0515	CbGpPWpGaD
Amprenavir—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000588	0.046	CbGpPWpGaD
Amprenavir—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00054	0.0423	CbGpPWpGaD
Amprenavir—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000536	0.0419	CbGpPWpGaD
Amprenavir—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000504	0.0395	CbGpPWpGaD
Amprenavir—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000482	0.0377	CbGpPWpGaD
Amprenavir—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000471	0.0369	CbGpPWpGaD
Amprenavir—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000408	0.0319	CbGpPWpGaD
Amprenavir—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000364	0.0285	CbGpPWpGaD
Amprenavir—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000335	0.0262	CbGpPWpGaD
Amprenavir—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000332	0.026	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL22—psoriasis	0.000285	0.0223	CbGpPWpGaD
Amprenavir—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000219	0.0171	CbGpPWpGaD
Amprenavir—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.0002	0.0157	CbGpPWpGaD
Amprenavir—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000197	0.0155	CbGpPWpGaD
Amprenavir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000196	0.0153	CbGpPWpGaD
Amprenavir—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000193	0.0151	CbGpPWpGaD
Amprenavir—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000169	0.0133	CbGpPWpGaD
Amprenavir—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000167	0.0131	CbGpPWpGaD
Amprenavir—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000162	0.0127	CbGpPWpGaD
Amprenavir—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000159	0.0124	CbGpPWpGaD
Amprenavir—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000151	0.0118	CbGpPWpGaD
Amprenavir—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000149	0.0117	CbGpPWpGaD
Amprenavir—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000139	0.0109	CbGpPWpGaD
Amprenavir—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000138	0.0108	CbGpPWpGaD
Amprenavir—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000137	0.0108	CbGpPWpGaD
Amprenavir—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000137	0.0107	CbGpPWpGaD
Amprenavir—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000136	0.0107	CbGpPWpGaD
Amprenavir—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000123	0.0096	CbGpPWpGaD
Amprenavir—Diabetes mellitus—Methotrexate—psoriasis	0.00012	0.00177	CcSEcCtD
Amprenavir—Myalgia—Mycophenolic acid—psoriasis	0.00012	0.00176	CcSEcCtD
Amprenavir—Diarrhoea—Acitretin—psoriasis	0.00012	0.00176	CcSEcCtD
Amprenavir—Myocardial infarction—Triamcinolone—psoriasis	0.00012	0.00176	CcSEcCtD
Amprenavir—Decreased appetite—Hydroxyurea—psoriasis	0.000119	0.00175	CcSEcCtD
Amprenavir—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000119	0.00175	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000119	0.00175	CcSEcCtD
Amprenavir—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000118	0.00174	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000118	0.00174	CcSEcCtD
Amprenavir—Discomfort—Mycophenolic acid—psoriasis	0.000118	0.00174	CcSEcCtD
Amprenavir—Fatigue—Hydroxyurea—psoriasis	0.000118	0.00174	CcSEcCtD
Amprenavir—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000118	0.00924	CbGpPWpGaD
Amprenavir—Nausea—Calcitriol—psoriasis	0.000117	0.00171	CcSEcCtD
Amprenavir—Mental disorder—Cyclosporine—psoriasis	0.000115	0.00168	CcSEcCtD
Amprenavir—Connective tissue disorder—Hydrocortisone—psoriasis	0.000114	0.00168	CcSEcCtD
Amprenavir—Malnutrition—Cyclosporine—psoriasis	0.000114	0.00167	CcSEcCtD
Amprenavir—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000113	0.00883	CbGpPWpGaD
Amprenavir—Nervous system disorder—Mycophenolic acid—psoriasis	0.000113	0.00166	CcSEcCtD
Amprenavir—Flatulence—Cyclosporine—psoriasis	0.000112	0.00165	CcSEcCtD
Amprenavir—Hyperglycaemia—Betamethasone—psoriasis	0.000112	0.00165	CcSEcCtD
Amprenavir—Hyperglycaemia—Dexamethasone—psoriasis	0.000112	0.00165	CcSEcCtD
Amprenavir—Mental disorder—Mycophenolate mofetil—psoriasis	0.000112	0.00164	CcSEcCtD
Amprenavir—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000112	0.00875	CbGpPWpGaD
Amprenavir—Skin disorder—Mycophenolic acid—psoriasis	0.000112	0.00164	CcSEcCtD
Amprenavir—Malnutrition—Mycophenolate mofetil—psoriasis	0.000111	0.00163	CcSEcCtD
Amprenavir—Vomiting—Acitretin—psoriasis	0.000111	0.00163	CcSEcCtD
Amprenavir—Vomiting—Fluocinolone Acetonide—psoriasis	0.000111	0.00163	CcSEcCtD
Amprenavir—Alanine aminotransferase increased—Prednisone—psoriasis	0.00011	0.00162	CcSEcCtD
Amprenavir—Rash—Acitretin—psoriasis	0.00011	0.00162	CcSEcCtD
Amprenavir—Dermatitis—Acitretin—psoriasis	0.00011	0.00162	CcSEcCtD
Amprenavir—Rash—Fluocinolone Acetonide—psoriasis	0.00011	0.00161	CcSEcCtD
Amprenavir—Dermatitis—Fluocinolone Acetonide—psoriasis	0.00011	0.00161	CcSEcCtD
Amprenavir—Anorexia—Mycophenolic acid—psoriasis	0.00011	0.00161	CcSEcCtD
Amprenavir—Flatulence—Mycophenolate mofetil—psoriasis	0.00011	0.00161	CcSEcCtD
Amprenavir—Headache—Acitretin—psoriasis	0.00011	0.00161	CcSEcCtD
Amprenavir—Headache—Fluocinolone Acetonide—psoriasis	0.000109	0.0016	CcSEcCtD
Amprenavir—Acute coronary syndrome—Dexamethasone—psoriasis	0.000109	0.0016	CcSEcCtD
Amprenavir—Acute coronary syndrome—Betamethasone—psoriasis	0.000109	0.0016	CcSEcCtD
Amprenavir—Myocardial infarction—Betamethasone—psoriasis	0.000109	0.00159	CcSEcCtD
Amprenavir—Myocardial infarction—Dexamethasone—psoriasis	0.000109	0.00159	CcSEcCtD
Amprenavir—Tremor—Cyclosporine—psoriasis	0.000107	0.00157	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000105	0.00154	CcSEcCtD
Amprenavir—Tremor—Mycophenolate mofetil—psoriasis	0.000104	0.00153	CcSEcCtD
Amprenavir—Angioedema—Cyclosporine—psoriasis	0.000104	0.00153	CcSEcCtD
Amprenavir—Nausea—Acitretin—psoriasis	0.000104	0.00153	CcSEcCtD
Amprenavir—Nausea—Fluocinolone Acetonide—psoriasis	0.000104	0.00152	CcSEcCtD
Amprenavir—Paraesthesia—Mycophenolic acid—psoriasis	0.000103	0.00152	CcSEcCtD
Amprenavir—Mental disorder—Hydrocortisone—psoriasis	0.000102	0.0015	CcSEcCtD
Amprenavir—Angioedema—Mycophenolate mofetil—psoriasis	0.000102	0.00149	CcSEcCtD
Amprenavir—Malnutrition—Hydrocortisone—psoriasis	0.000101	0.00149	CcSEcCtD
Amprenavir—Neutropenia—Prednisone—psoriasis	0.000101	0.00149	CcSEcCtD
Amprenavir—Decreased appetite—Mycophenolic acid—psoriasis	9.99e-05	0.00147	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Mycophenolic acid—psoriasis	9.92e-05	0.00146	CcSEcCtD
Amprenavir—Fatigue—Mycophenolic acid—psoriasis	9.91e-05	0.00146	CcSEcCtD
Amprenavir—Asthenia—Hydroxyurea—psoriasis	9.85e-05	0.00145	CcSEcCtD
Amprenavir—ABCC1—S1P1 pathway—VEGFA—psoriasis	9.81e-05	0.00768	CbGpPWpGaD
Amprenavir—Hyperglycaemia—Prednisone—psoriasis	9.75e-05	0.00143	CcSEcCtD
Amprenavir—Myalgia—Cyclosporine—psoriasis	9.7e-05	0.00143	CcSEcCtD
Amprenavir—Liver function test abnormal—Methotrexate—psoriasis	9.65e-05	0.00142	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	9.63e-05	0.00142	CcSEcCtD
Amprenavir—Depression—Prednisone—psoriasis	9.61e-05	0.00141	CcSEcCtD
Amprenavir—Discomfort—Cyclosporine—psoriasis	9.58e-05	0.00141	CcSEcCtD
Amprenavir—Acute coronary syndrome—Prednisone—psoriasis	9.5e-05	0.0014	CcSEcCtD
Amprenavir—Angioedema—Prednisolone—psoriasis	9.47e-05	0.00139	CcSEcCtD
Amprenavir—Myalgia—Mycophenolate mofetil—psoriasis	9.46e-05	0.00139	CcSEcCtD
Amprenavir—Myocardial infarction—Prednisone—psoriasis	9.45e-05	0.00139	CcSEcCtD
Amprenavir—Gastrointestinal pain—Mycophenolic acid—psoriasis	9.4e-05	0.00138	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	9.4e-05	0.00138	CcSEcCtD
Amprenavir—Diarrhoea—Hydroxyurea—psoriasis	9.39e-05	0.00138	CcSEcCtD
Amprenavir—Discomfort—Mycophenolate mofetil—psoriasis	9.35e-05	0.00137	CcSEcCtD
Amprenavir—Angioedema—Hydrocortisone—psoriasis	9.25e-05	0.00136	CcSEcCtD
Amprenavir—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.19e-05	0.0072	CbGpPWpGaD
Amprenavir—Nervous system disorder—Cyclosporine—psoriasis	9.12e-05	0.00134	CcSEcCtD
Amprenavir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.09e-05	0.00712	CbGpPWpGaD
Amprenavir—Abdominal pain—Mycophenolic acid—psoriasis	9.09e-05	0.00133	CcSEcCtD
Amprenavir—Skin disorder—Cyclosporine—psoriasis	9.03e-05	0.00133	CcSEcCtD
Amprenavir—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.97e-05	0.00703	CbGpPWpGaD
Amprenavir—Nervous system disorder—Mycophenolate mofetil—psoriasis	8.9e-05	0.00131	CcSEcCtD
Amprenavir—Anorexia—Cyclosporine—psoriasis	8.86e-05	0.0013	CcSEcCtD
Amprenavir—Skin disorder—Mycophenolate mofetil—psoriasis	8.81e-05	0.00129	CcSEcCtD
Amprenavir—Vomiting—Hydroxyurea—psoriasis	8.73e-05	0.00128	CcSEcCtD
Amprenavir—Discomfort—Prednisolone—psoriasis	8.72e-05	0.00128	CcSEcCtD
Amprenavir—Angioedema—Triamcinolone—psoriasis	8.71e-05	0.00128	CcSEcCtD
Amprenavir—Abdominal discomfort—Methotrexate—psoriasis	8.66e-05	0.00127	CcSEcCtD
Amprenavir—Rash—Hydroxyurea—psoriasis	8.65e-05	0.00127	CcSEcCtD
Amprenavir—Anorexia—Mycophenolate mofetil—psoriasis	8.65e-05	0.00127	CcSEcCtD
Amprenavir—Dermatitis—Hydroxyurea—psoriasis	8.65e-05	0.00127	CcSEcCtD
Amprenavir—Myalgia—Hydrocortisone—psoriasis	8.62e-05	0.00127	CcSEcCtD
Amprenavir—CYP2B6—Biological oxidations—CYP2S1—psoriasis	8.62e-05	0.00675	CbGpPWpGaD
Amprenavir—Headache—Hydroxyurea—psoriasis	8.6e-05	0.00126	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	8.56e-05	0.00126	CcSEcCtD
Amprenavir—Discomfort—Hydrocortisone—psoriasis	8.52e-05	0.00125	CcSEcCtD
Amprenavir—Connective tissue disorder—Prednisone—psoriasis	8.5e-05	0.00125	CcSEcCtD
Amprenavir—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	8.5e-05	0.00665	CbGpPWpGaD
Amprenavir—Musculoskeletal discomfort—Cyclosporine—psoriasis	8.47e-05	0.00124	CcSEcCtD
Amprenavir—Neutropenia—Methotrexate—psoriasis	8.45e-05	0.00124	CcSEcCtD
Amprenavir—CYP3A5—Biological oxidations—CYP2S1—psoriasis	8.42e-05	0.00659	CbGpPWpGaD
Amprenavir—Paraesthesia—Cyclosporine—psoriasis	8.35e-05	0.00123	CcSEcCtD
Amprenavir—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	8.31e-05	0.0065	CbGpPWpGaD
Amprenavir—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	8.26e-05	0.00121	CcSEcCtD
Amprenavir—Asthenia—Mycophenolic acid—psoriasis	8.25e-05	0.00121	CcSEcCtD
Amprenavir—Nausea—Hydroxyurea—psoriasis	8.15e-05	0.0012	CcSEcCtD
Amprenavir—Paraesthesia—Mycophenolate mofetil—psoriasis	8.15e-05	0.0012	CcSEcCtD
Amprenavir—Pruritus—Mycophenolic acid—psoriasis	8.13e-05	0.00119	CcSEcCtD
Amprenavir—Myalgia—Triamcinolone—psoriasis	8.12e-05	0.00119	CcSEcCtD
Amprenavir—Nervous system disorder—Hydrocortisone—psoriasis	8.1e-05	0.00119	CcSEcCtD
Amprenavir—Decreased appetite—Cyclosporine—psoriasis	8.08e-05	0.00119	CcSEcCtD
Amprenavir—Depression—Methotrexate—psoriasis	8.03e-05	0.00118	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Cyclosporine—psoriasis	8.03e-05	0.00118	CcSEcCtD
Amprenavir—Skin disorder—Hydrocortisone—psoriasis	8.03e-05	0.00118	CcSEcCtD
Amprenavir—Discomfort—Triamcinolone—psoriasis	8.02e-05	0.00118	CcSEcCtD
Amprenavir—Fatigue—Cyclosporine—psoriasis	8.02e-05	0.00118	CcSEcCtD
Amprenavir—Stevens-Johnson syndrome—Methotrexate—psoriasis	7.99e-05	0.00117	CcSEcCtD
Amprenavir—Angioedema—Betamethasone—psoriasis	7.91e-05	0.00116	CcSEcCtD
Amprenavir—Angioedema—Dexamethasone—psoriasis	7.91e-05	0.00116	CcSEcCtD
Amprenavir—Decreased appetite—Mycophenolate mofetil—psoriasis	7.89e-05	0.00116	CcSEcCtD
Amprenavir—Anorexia—Hydrocortisone—psoriasis	7.88e-05	0.00116	CcSEcCtD
Amprenavir—Diarrhoea—Mycophenolic acid—psoriasis	7.86e-05	0.00116	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	7.83e-05	0.00115	CcSEcCtD
Amprenavir—Hepatobiliary disease—Methotrexate—psoriasis	7.62e-05	0.00112	CcSEcCtD
Amprenavir—Gastrointestinal pain—Cyclosporine—psoriasis	7.6e-05	0.00112	CcSEcCtD
Amprenavir—Paraesthesia—Prednisolone—psoriasis	7.6e-05	0.00112	CcSEcCtD
Amprenavir—Mental disorder—Prednisone—psoriasis	7.58e-05	0.00111	CcSEcCtD
Amprenavir—Malnutrition—Prednisone—psoriasis	7.53e-05	0.00111	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.53e-05	0.00111	CcSEcCtD
Amprenavir—Paraesthesia—Hydrocortisone—psoriasis	7.42e-05	0.00109	CcSEcCtD
Amprenavir—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.42e-05	0.00109	CcSEcCtD
Amprenavir—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.37e-05	0.00577	CbGpPWpGaD
Amprenavir—Myalgia—Dexamethasone—psoriasis	7.37e-05	0.00108	CcSEcCtD
Amprenavir—Myalgia—Betamethasone—psoriasis	7.37e-05	0.00108	CcSEcCtD
Amprenavir—Abdominal pain—Cyclosporine—psoriasis	7.35e-05	0.00108	CcSEcCtD
Amprenavir—Vomiting—Mycophenolic acid—psoriasis	7.31e-05	0.00107	CcSEcCtD
Amprenavir—CYP2C8—Biological oxidations—CYP2S1—psoriasis	7.3e-05	0.00571	CbGpPWpGaD
Amprenavir—Discomfort—Betamethasone—psoriasis	7.28e-05	0.00107	CcSEcCtD
Amprenavir—Discomfort—Dexamethasone—psoriasis	7.28e-05	0.00107	CcSEcCtD
Amprenavir—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.27e-05	0.00569	CbGpPWpGaD
Amprenavir—Rash—Mycophenolic acid—psoriasis	7.25e-05	0.00106	CcSEcCtD
Amprenavir—Dermatitis—Mycophenolic acid—psoriasis	7.24e-05	0.00106	CcSEcCtD
Amprenavir—Headache—Mycophenolic acid—psoriasis	7.2e-05	0.00106	CcSEcCtD
Amprenavir—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	7.2e-05	0.00563	CbGpPWpGaD
Amprenavir—Decreased appetite—Hydrocortisone—psoriasis	7.18e-05	0.00106	CcSEcCtD
Amprenavir—Abdominal pain—Mycophenolate mofetil—psoriasis	7.17e-05	0.00105	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.13e-05	0.00105	CcSEcCtD
Amprenavir—Fatigue—Hydrocortisone—psoriasis	7.13e-05	0.00105	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.09e-05	0.00104	CcSEcCtD
Amprenavir—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	7e-05	0.00548	CbGpPWpGaD
Amprenavir—Paraesthesia—Triamcinolone—psoriasis	6.99e-05	0.00103	CcSEcCtD
Amprenavir—Nervous system disorder—Betamethasone—psoriasis	6.92e-05	0.00102	CcSEcCtD
Amprenavir—Nervous system disorder—Dexamethasone—psoriasis	6.92e-05	0.00102	CcSEcCtD
Amprenavir—Angioedema—Prednisone—psoriasis	6.88e-05	0.00101	CcSEcCtD
Amprenavir—Erythema multiforme—Methotrexate—psoriasis	6.84e-05	0.001	CcSEcCtD
Amprenavir—Nausea—Mycophenolic acid—psoriasis	6.83e-05	0.001	CcSEcCtD
Amprenavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.78e-05	0.00531	CbGpPWpGaD
Amprenavir—Gastrointestinal pain—Hydrocortisone—psoriasis	6.76e-05	0.000993	CcSEcCtD
Amprenavir—Anorexia—Dexamethasone—psoriasis	6.73e-05	0.000989	CcSEcCtD
Amprenavir—Anorexia—Betamethasone—psoriasis	6.73e-05	0.000989	CcSEcCtD
Amprenavir—Cardiac disorder—Methotrexate—psoriasis	6.71e-05	0.000986	CcSEcCtD
Amprenavir—Fatigue—Triamcinolone—psoriasis	6.71e-05	0.000986	CcSEcCtD
Amprenavir—Asthenia—Cyclosporine—psoriasis	6.67e-05	0.00098	CcSEcCtD
Amprenavir—Pruritus—Cyclosporine—psoriasis	6.58e-05	0.000967	CcSEcCtD
Amprenavir—Abdominal pain—Hydrocortisone—psoriasis	6.53e-05	0.00096	CcSEcCtD
Amprenavir—CYP2C19—Biological oxidations—CYP2S1—psoriasis	6.51e-05	0.0051	CbGpPWpGaD
Amprenavir—Asthenia—Mycophenolate mofetil—psoriasis	6.51e-05	0.000956	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.43e-05	0.000945	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Betamethasone—psoriasis	6.43e-05	0.000945	CcSEcCtD
Amprenavir—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	6.42e-05	0.00503	CbGpPWpGaD
Amprenavir—Pruritus—Mycophenolate mofetil—psoriasis	6.42e-05	0.000943	CcSEcCtD
Amprenavir—Myalgia—Prednisone—psoriasis	6.41e-05	0.000942	CcSEcCtD
Amprenavir—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.41e-05	0.00502	CbGpPWpGaD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.37e-05	0.000936	CcSEcCtD
Amprenavir—Diarrhoea—Cyclosporine—psoriasis	6.36e-05	0.000935	CcSEcCtD
Amprenavir—Paraesthesia—Dexamethasone—psoriasis	6.34e-05	0.000931	CcSEcCtD
Amprenavir—Paraesthesia—Betamethasone—psoriasis	6.34e-05	0.000931	CcSEcCtD
Amprenavir—Discomfort—Prednisone—psoriasis	6.34e-05	0.000931	CcSEcCtD
Amprenavir—Mental disorder—Methotrexate—psoriasis	6.34e-05	0.000931	CcSEcCtD
Amprenavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.33e-05	0.00496	CbGpPWpGaD
Amprenavir—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	6.31e-05	0.00494	CbGpPWpGaD
Amprenavir—Malnutrition—Methotrexate—psoriasis	6.3e-05	0.000925	CcSEcCtD
Amprenavir—Diarrhoea—Mycophenolate mofetil—psoriasis	6.21e-05	0.000912	CcSEcCtD
Amprenavir—Decreased appetite—Dexamethasone—psoriasis	6.14e-05	0.000902	CcSEcCtD
Amprenavir—Decreased appetite—Betamethasone—psoriasis	6.14e-05	0.000902	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Betamethasone—psoriasis	6.1e-05	0.000896	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Dexamethasone—psoriasis	6.1e-05	0.000896	CcSEcCtD
Amprenavir—Fatigue—Dexamethasone—psoriasis	6.09e-05	0.000894	CcSEcCtD
Amprenavir—Fatigue—Betamethasone—psoriasis	6.09e-05	0.000894	CcSEcCtD
Amprenavir—Nervous system disorder—Prednisone—psoriasis	6.03e-05	0.000886	CcSEcCtD
Amprenavir—CYP2D6—Biological oxidations—CYP2S1—psoriasis	5.99e-05	0.00469	CbGpPWpGaD
Amprenavir—Skin disorder—Prednisone—psoriasis	5.97e-05	0.000877	CcSEcCtD
Amprenavir—CYP2C9—Biological oxidations—CYP2S1—psoriasis	5.94e-05	0.00465	CbGpPWpGaD
Amprenavir—Asthenia—Hydrocortisone—psoriasis	5.93e-05	0.000871	CcSEcCtD
Amprenavir—Vomiting—Cyclosporine—psoriasis	5.91e-05	0.000869	CcSEcCtD
Amprenavir—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	5.91e-05	0.00462	CbGpPWpGaD
Amprenavir—Rash—Cyclosporine—psoriasis	5.86e-05	0.000861	CcSEcCtD
Amprenavir—Anorexia—Prednisone—psoriasis	5.86e-05	0.000861	CcSEcCtD
Amprenavir—Dermatitis—Cyclosporine—psoriasis	5.86e-05	0.000861	CcSEcCtD
Amprenavir—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	5.86e-05	0.00458	CbGpPWpGaD
Amprenavir—Pruritus—Hydrocortisone—psoriasis	5.85e-05	0.000859	CcSEcCtD
Amprenavir—Headache—Cyclosporine—psoriasis	5.83e-05	0.000856	CcSEcCtD
Amprenavir—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	5.81e-05	0.00455	CbGpPWpGaD
Amprenavir—Gastrointestinal pain—Betamethasone—psoriasis	5.77e-05	0.000848	CcSEcCtD
Amprenavir—Gastrointestinal pain—Dexamethasone—psoriasis	5.77e-05	0.000848	CcSEcCtD
Amprenavir—Vomiting—Mycophenolate mofetil—psoriasis	5.77e-05	0.000847	CcSEcCtD
Amprenavir—Rash—Mycophenolate mofetil—psoriasis	5.72e-05	0.00084	CcSEcCtD
Amprenavir—Dermatitis—Mycophenolate mofetil—psoriasis	5.71e-05	0.000839	CcSEcCtD
Amprenavir—Headache—Mycophenolate mofetil—psoriasis	5.68e-05	0.000835	CcSEcCtD
Amprenavir—Diarrhoea—Hydrocortisone—psoriasis	5.65e-05	0.000831	CcSEcCtD
Amprenavir—Musculoskeletal discomfort—Prednisone—psoriasis	5.6e-05	0.000823	CcSEcCtD
Amprenavir—Asthenia—Triamcinolone—psoriasis	5.58e-05	0.00082	CcSEcCtD
Amprenavir—Abdominal pain—Betamethasone—psoriasis	5.58e-05	0.00082	CcSEcCtD
Amprenavir—Abdominal pain—Dexamethasone—psoriasis	5.58e-05	0.00082	CcSEcCtD
Amprenavir—Nausea—Cyclosporine—psoriasis	5.52e-05	0.000811	CcSEcCtD
Amprenavir—Paraesthesia—Prednisone—psoriasis	5.52e-05	0.000811	CcSEcCtD
Amprenavir—Pruritus—Triamcinolone—psoriasis	5.51e-05	0.000809	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.4e-05	0.00423	CbGpPWpGaD
Amprenavir—Nausea—Mycophenolate mofetil—psoriasis	5.39e-05	0.000792	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—IL13—psoriasis	5.37e-05	0.0042	CbGpPWpGaD
Amprenavir—Myalgia—Methotrexate—psoriasis	5.36e-05	0.000788	CcSEcCtD
Amprenavir—Decreased appetite—Prednisone—psoriasis	5.35e-05	0.000785	CcSEcCtD
Amprenavir—Rash—Prednisolone—psoriasis	5.34e-05	0.000784	CcSEcCtD
Amprenavir—Dermatitis—Prednisolone—psoriasis	5.33e-05	0.000783	CcSEcCtD
Amprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.32e-05	0.000782	CcSEcCtD
Amprenavir—Fatigue—Prednisone—psoriasis	5.3e-05	0.000779	CcSEcCtD
Amprenavir—Headache—Prednisolone—psoriasis	5.3e-05	0.000779	CcSEcCtD
Amprenavir—Discomfort—Methotrexate—psoriasis	5.3e-05	0.000778	CcSEcCtD
Amprenavir—Vomiting—Hydrocortisone—psoriasis	5.25e-05	0.000772	CcSEcCtD
Amprenavir—Rash—Hydrocortisone—psoriasis	5.21e-05	0.000766	CcSEcCtD
Amprenavir—Dermatitis—Hydrocortisone—psoriasis	5.21e-05	0.000765	CcSEcCtD
Amprenavir—Headache—Hydrocortisone—psoriasis	5.18e-05	0.000761	CcSEcCtD
Amprenavir—Asthenia—Dexamethasone—psoriasis	5.07e-05	0.000744	CcSEcCtD
Amprenavir—Asthenia—Betamethasone—psoriasis	5.07e-05	0.000744	CcSEcCtD
Amprenavir—Nervous system disorder—Methotrexate—psoriasis	5.04e-05	0.00074	CcSEcCtD
Amprenavir—Gastrointestinal pain—Prednisone—psoriasis	5.03e-05	0.000739	CcSEcCtD
Amprenavir—Nausea—Prednisolone—psoriasis	5.03e-05	0.000738	CcSEcCtD
Amprenavir—Pruritus—Dexamethasone—psoriasis	5e-05	0.000734	CcSEcCtD
Amprenavir—Pruritus—Betamethasone—psoriasis	5e-05	0.000734	CcSEcCtD
Amprenavir—Skin disorder—Methotrexate—psoriasis	4.99e-05	0.000733	CcSEcCtD
Amprenavir—Vomiting—Triamcinolone—psoriasis	4.95e-05	0.000727	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—IL17A—psoriasis	4.94e-05	0.00387	CbGpPWpGaD
Amprenavir—Nausea—Hydrocortisone—psoriasis	4.91e-05	0.000721	CcSEcCtD
Amprenavir—Rash—Triamcinolone—psoriasis	4.91e-05	0.000721	CcSEcCtD
Amprenavir—Dermatitis—Triamcinolone—psoriasis	4.9e-05	0.00072	CcSEcCtD
Amprenavir—Anorexia—Methotrexate—psoriasis	4.9e-05	0.00072	CcSEcCtD
Amprenavir—Headache—Triamcinolone—psoriasis	4.87e-05	0.000716	CcSEcCtD
Amprenavir—Abdominal pain—Prednisone—psoriasis	4.86e-05	0.000714	CcSEcCtD
Amprenavir—Diarrhoea—Dexamethasone—psoriasis	4.83e-05	0.00071	CcSEcCtD
Amprenavir—Diarrhoea—Betamethasone—psoriasis	4.83e-05	0.00071	CcSEcCtD
Amprenavir—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.73e-05	0.0037	CbGpPWpGaD
Amprenavir—Musculoskeletal discomfort—Methotrexate—psoriasis	4.68e-05	0.000688	CcSEcCtD
Amprenavir—Nausea—Triamcinolone—psoriasis	4.62e-05	0.000679	CcSEcCtD
Amprenavir—Paraesthesia—Methotrexate—psoriasis	4.61e-05	0.000678	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—IL12B—psoriasis	4.6e-05	0.0036	CbGpPWpGaD
Amprenavir—Vomiting—Dexamethasone—psoriasis	4.49e-05	0.00066	CcSEcCtD
Amprenavir—Vomiting—Betamethasone—psoriasis	4.49e-05	0.00066	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.49e-05	0.00351	CbGpPWpGaD
Amprenavir—Decreased appetite—Methotrexate—psoriasis	4.47e-05	0.000656	CcSEcCtD
Amprenavir—Rash—Dexamethasone—psoriasis	4.45e-05	0.000654	CcSEcCtD
Amprenavir—Rash—Betamethasone—psoriasis	4.45e-05	0.000654	CcSEcCtD
Amprenavir—Dermatitis—Betamethasone—psoriasis	4.45e-05	0.000653	CcSEcCtD
Amprenavir—Dermatitis—Dexamethasone—psoriasis	4.45e-05	0.000653	CcSEcCtD
Amprenavir—Gastrointestinal disorder—Methotrexate—psoriasis	4.44e-05	0.000652	CcSEcCtD
Amprenavir—Fatigue—Methotrexate—psoriasis	4.43e-05	0.000651	CcSEcCtD
Amprenavir—Headache—Betamethasone—psoriasis	4.42e-05	0.00065	CcSEcCtD
Amprenavir—Headache—Dexamethasone—psoriasis	4.42e-05	0.00065	CcSEcCtD
Amprenavir—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.42e-05	0.00346	CbGpPWpGaD
Amprenavir—Asthenia—Prednisone—psoriasis	4.41e-05	0.000648	CcSEcCtD
Amprenavir—Pruritus—Prednisone—psoriasis	4.35e-05	0.000639	CcSEcCtD
Amprenavir—Diarrhoea—Prednisone—psoriasis	4.21e-05	0.000618	CcSEcCtD
Amprenavir—Gastrointestinal pain—Methotrexate—psoriasis	4.2e-05	0.000617	CcSEcCtD
Amprenavir—Nausea—Betamethasone—psoriasis	4.19e-05	0.000616	CcSEcCtD
Amprenavir—Nausea—Dexamethasone—psoriasis	4.19e-05	0.000616	CcSEcCtD
Amprenavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.18e-05	0.00327	CbGpPWpGaD
Amprenavir—Abdominal pain—Methotrexate—psoriasis	4.06e-05	0.000597	CcSEcCtD
Amprenavir—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.92e-05	0.00307	CbGpPWpGaD
Amprenavir—Vomiting—Prednisone—psoriasis	3.91e-05	0.000574	CcSEcCtD
Amprenavir—Rash—Prednisone—psoriasis	3.88e-05	0.00057	CcSEcCtD
Amprenavir—Dermatitis—Prednisone—psoriasis	3.87e-05	0.000569	CcSEcCtD
Amprenavir—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.86e-05	0.00302	CbGpPWpGaD
Amprenavir—Headache—Prednisone—psoriasis	3.85e-05	0.000566	CcSEcCtD
Amprenavir—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	3.75e-05	0.00294	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.71e-05	0.00291	CbGpPWpGaD
Amprenavir—Asthenia—Methotrexate—psoriasis	3.69e-05	0.000542	CcSEcCtD
Amprenavir—Nausea—Prednisone—psoriasis	3.65e-05	0.000537	CcSEcCtD
Amprenavir—Pruritus—Methotrexate—psoriasis	3.64e-05	0.000534	CcSEcCtD
Amprenavir—Diarrhoea—Methotrexate—psoriasis	3.52e-05	0.000517	CcSEcCtD
Amprenavir—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.45e-05	0.0027	CbGpPWpGaD
Amprenavir—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.38e-05	0.00264	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL10—psoriasis	3.36e-05	0.00263	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IL4—psoriasis	3.27e-05	0.00256	CbGpPWpGaD
Amprenavir—Vomiting—Methotrexate—psoriasis	3.27e-05	0.00048	CcSEcCtD
Amprenavir—Rash—Methotrexate—psoriasis	3.24e-05	0.000476	CcSEcCtD
Amprenavir—Dermatitis—Methotrexate—psoriasis	3.24e-05	0.000476	CcSEcCtD
Amprenavir—Headache—Methotrexate—psoriasis	3.22e-05	0.000473	CcSEcCtD
Amprenavir—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.2e-05	0.0025	CbGpPWpGaD
Amprenavir—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.19e-05	0.0025	CbGpPWpGaD
Amprenavir—Nausea—Methotrexate—psoriasis	3.05e-05	0.000448	CcSEcCtD
Amprenavir—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.97e-05	0.00233	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.96e-05	0.00232	CbGpPWpGaD
Amprenavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.91e-05	0.00228	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.71e-05	0.00212	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.0021	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.51e-05	0.00196	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	2.5e-05	0.00195	CbGpPWpGaD
Amprenavir—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	2.38e-05	0.00186	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—CYP2S1—psoriasis	2.28e-05	0.00179	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—IFNG—psoriasis	1.98e-05	0.00155	CbGpPWpGaD
Amprenavir—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.97e-05	0.00154	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.84e-05	0.00144	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—NDUFA5—psoriasis	1.73e-05	0.00136	CbGpPWpGaD
Amprenavir—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.72e-05	0.00135	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—NDUFA5—psoriasis	1.69e-05	0.00133	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.51e-05	0.00118	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.49e-05	0.00117	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CYP2S1—psoriasis	1.47e-05	0.00115	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—NDUFA5—psoriasis	1.47e-05	0.00115	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CYP2S1—psoriasis	1.44e-05	0.00113	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.37e-05	0.00107	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—NDUFA5—psoriasis	1.31e-05	0.00103	CbGpPWpGaD
Amprenavir—ABCB1—Allograft Rejection—TNF—psoriasis	1.28e-05	0.001	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—NDUFA5—psoriasis	1.28e-05	0.001	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.27e-05	0.000995	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CYP2S1—psoriasis	1.25e-05	0.000977	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.22e-05	0.000956	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—NDUFA5—psoriasis	1.2e-05	0.000943	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.2e-05	0.000937	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—NDUFA5—psoriasis	1.19e-05	0.000935	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.19e-05	0.00093	CbGpPWpGaD
Amprenavir—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.13e-05	0.000887	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—CARM1—psoriasis	1.12e-05	0.000873	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CYP2S1—psoriasis	1.11e-05	0.000872	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.11e-05	0.000872	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CYP2S1—psoriasis	1.09e-05	0.000851	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000816	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CYP2S1—psoriasis	1.02e-05	0.000802	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CYP2S1—psoriasis	1.02e-05	0.000795	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.43e-06	0.00066	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.11e-06	0.000635	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—NDUFA5—psoriasis	7.88e-06	0.000617	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.36e-06	0.000576	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CARM1—psoriasis	7.2e-06	0.000563	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CARM1—psoriasis	7.03e-06	0.000551	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—CAT—psoriasis	6.86e-06	0.000537	CbGpPWpGaD
Amprenavir—ABCC1—Disease—HLA-A—psoriasis	6.82e-06	0.000534	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CYP2S1—psoriasis	6.7e-06	0.000524	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.54e-06	0.000512	CbGpPWpGaD
Amprenavir—ABCC1—Disease—APOE—psoriasis	6.37e-06	0.000498	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.31e-06	0.000494	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CARM1—psoriasis	6.09e-06	0.000477	CbGpPWpGaD
Amprenavir—ABCC1—Disease—NOS2—psoriasis	5.93e-06	0.000464	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.84e-06	0.000457	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.7e-06	0.000446	CbGpPWpGaD
Amprenavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.56e-06	0.000436	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CARM1—psoriasis	5.44e-06	0.000426	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—APOE—psoriasis	5.33e-06	0.000417	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.32e-06	0.000417	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CARM1—psoriasis	5.31e-06	0.000416	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.08e-06	0.000398	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CARM1—psoriasis	5e-06	0.000392	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CARM1—psoriasis	4.96e-06	0.000388	CbGpPWpGaD
Amprenavir—ABCC1—Disease—TYK2—psoriasis	4.86e-06	0.00038	CbGpPWpGaD
Amprenavir—ABCC1—Metabolism—PPARG—psoriasis	4.64e-06	0.000364	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.64e-06	0.000363	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—CAT—psoriasis	4.43e-06	0.000347	CbGpPWpGaD
Amprenavir—ABCC1—Disease—CD4—psoriasis	4.4e-06	0.000344	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—CAT—psoriasis	4.33e-06	0.000339	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—CAT—psoriasis	3.75e-06	0.000293	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—APOE—psoriasis	3.44e-06	0.000269	CbGpPWpGaD
Amprenavir—ABCC1—Disease—STAT3—psoriasis	3.4e-06	0.000266	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—APOE—psoriasis	3.36e-06	0.000263	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—CAT—psoriasis	3.35e-06	0.000262	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CARM1—psoriasis	3.27e-06	0.000256	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—CAT—psoriasis	3.27e-06	0.000256	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—CAT—psoriasis	3.08e-06	0.000241	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—CAT—psoriasis	3.05e-06	0.000239	CbGpPWpGaD
Amprenavir—CYP2B6—Metabolism—PPARG—psoriasis	3e-06	0.000235	CbGpPWpGaD
Amprenavir—CYP3A5—Metabolism—PPARG—psoriasis	2.93e-06	0.000229	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—APOE—psoriasis	2.91e-06	0.000228	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—APOE—psoriasis	2.6e-06	0.000203	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—APOE—psoriasis	2.54e-06	0.000199	CbGpPWpGaD
Amprenavir—CYP2C8—Metabolism—PPARG—psoriasis	2.54e-06	0.000199	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—APOE—psoriasis	2.39e-06	0.000187	CbGpPWpGaD
Amprenavir—ABCC1—Disease—IL6—psoriasis	2.38e-06	0.000186	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—APOE—psoriasis	2.37e-06	0.000186	CbGpPWpGaD
Amprenavir—CYP2C19—Metabolism—PPARG—psoriasis	2.26e-06	0.000177	CbGpPWpGaD
Amprenavir—ABCB1—Metabolism—PPARG—psoriasis	2.21e-06	0.000173	CbGpPWpGaD
Amprenavir—CYP2D6—Metabolism—PPARG—psoriasis	2.08e-06	0.000163	CbGpPWpGaD
Amprenavir—CYP2C9—Metabolism—PPARG—psoriasis	2.06e-06	0.000162	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—CAT—psoriasis	2.01e-06	0.000157	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—APOE—psoriasis	1.56e-06	0.000122	CbGpPWpGaD
Amprenavir—CYP3A4—Metabolism—PPARG—psoriasis	1.36e-06	0.000107	CbGpPWpGaD
